These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

160 related items for PubMed ID: 9597427

  • 1. Cost-effectiveness of primary and secondary prevention in cardiovascular diseases.
    Troche CJ, Tacke J, Hinzpeter B, Danner M, Lauterbach KW.
    Eur Heart J; 1998 Apr; 19 Suppl C():C59-65. PubMed ID: 9597427
    [Abstract] [Full Text] [Related]

  • 2. Results of a Markov model analysis to assess the cost-effectiveness of statin therapy for the primary prevention of cardiovascular disease in Korea: the Korean Individual-Microsimulation Model for Cardiovascular Health Interventions.
    Kang HY, Ko SK, Liew D.
    Clin Ther; 2009 Dec; 31(12):2919-30; discussion 2916-8. PubMed ID: 20110032
    [Abstract] [Full Text] [Related]

  • 3. Cost-effectiveness of high-dose atorvastatin compared with regular dose simvastatin.
    Lindgren P, Graff J, Olsson AG, Pedersen TJ, Jönsson B, IDEAL Trial Investigators.
    Eur Heart J; 2007 Jun; 28(12):1448-53. PubMed ID: 17371782
    [Abstract] [Full Text] [Related]

  • 4. Cost-effectiveness of lipid-lowering treatment according to lipid level.
    Pilote L, Ho V, Lavoie F, Coupal L, Zowall H, Grover SA.
    Can J Cardiol; 2005 Jun; 21(8):681-7. PubMed ID: 16003451
    [Abstract] [Full Text] [Related]

  • 5. Rosuvastatin is cost-effective in treating patients to low-density lipoprotein-cholesterol goals compared with atorvastatin, pravastatin and simvastatin: analysis of the STELLAR trial.
    Hirsch M, O'Donnell JC, Jones P.
    Eur J Cardiovasc Prev Rehabil; 2005 Feb; 12(1):18-28. PubMed ID: 15703502
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. The cost-effectiveness of implementing a new guideline for cardiovascular risk management in primary care in the Netherlands.
    Kok L, Engelfriet P, Jacobs-van der Bruggen MA, Hoogenveen RT, Boshuizen HC, Verschuren MW.
    Eur J Cardiovasc Prev Rehabil; 2009 Jun; 16(3):371-6. PubMed ID: 19305351
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. The value of atorvastatin over the product life cycle in the United States.
    Grabner M, Johnson W, Abdulhalim AM, Kuznik A, Mullins CD.
    Clin Ther; 2011 Oct; 33(10):1433-43. PubMed ID: 21955936
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Cost-effectiveness of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors in the secondary prevention of cardiovascular disease: forecasting the incremental benefits of preventing coronary and cerebrovascular events.
    Grover SA, Coupal L, Paquet S, Zowall H.
    Arch Intern Med; 1999 Mar 22; 159(6):593-600. PubMed ID: 10090116
    [Abstract] [Full Text] [Related]

  • 18. Cost-effectiveness of rosuvastatin 20 mg for the prevention of cardiovascular morbidity and mortality: a Swedish economic evaluation of the JUPITER trial.
    Ohsfeldt RL, Olsson AG, Jensen MM, Gandhi SK, Paulsson T.
    J Med Econ; 2012 Mar 22; 15(1):125-33. PubMed ID: 22050473
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.